B7-33 Peptide: RXFP1 Signaling, Relaxin Biology and Fibrosis Research
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2. It was designed to preserve selected signaling effects of relaxin while using a much simpler molecular structure than the native two-chain hormone.
Research on B7-33 has focused mainly on the relaxin family peptide receptor 1 (RXFP1), biased or functionally selective signaling, and preclinical models of fibrosis. This guide reviews the proposed mechanism, the evidence supporting anti-fibrotic research interest, and the limitations of the current data.
What Is B7-33?
Human relaxin-2 is an insulin-like peptide hormone consisting of two peptide chains connected by disulfide bonds. That structure contributes to biological activity but also makes synthesis and formulation more complex.
B7-33 was developed as a smaller linear peptide based mainly on the relaxin B-chain. The design aimed to retain activity at RXFP1 while simplifying the molecular scaffold.
B7-33 Research at a Glance
| Area | What has been studied |
|---|---|
| Origin | Single-chain analogue derived from human relaxin-2 B-chain |
| Primary receptor | RXFP1 |
| Signaling interest | Functionally selective / biased signaling, including ERK pathways |
| Main research area | Fibrosis and tissue-remodeling models |
| Evidence maturity | Predominantly cell and animal research |
Why RXFP1 Matters
RXFP1 is the primary receptor for relaxin-2. Activation of this G-protein-coupled receptor can influence multiple downstream signaling pathways, including cyclic AMP and ERK-related signaling.
Native relaxin produces a broad signaling profile. B7-33 was designed as a more selective agonist that may favor some downstream pathways over others, which makes it useful for studying how different RXFP1 signals contribute to biological effects.
What Does Functionally Selective Signaling Mean?
A receptor does not always produce one fixed output. Different ligands can stabilize different receptor states and therefore favor distinct intracellular pathways. This concept is often called biased agonism or functional selectivity.
In the original B7-33 research, the peptide was reported to activate RXFP1 while favoring ERK-associated signaling relative to strong cAMP signaling in relevant cell systems. Researchers proposed that this selective profile could help preserve anti-fibrotic activity while reducing some unwanted signaling associated with native relaxin.
Anti-Fibrotic Research
Fibrosis involves excessive deposition and remodeling of extracellular matrix, particularly collagen. It is a common feature of chronic injury across organs including the heart, lungs, kidneys and liver.
Preclinical studies have investigated B7-33 in several fibrosis models. The original development work reported prevention or reversal of fibrosis in rodent models of cardiac and pulmonary disease, with activity linked to RXFP1 signaling and matrix-remodeling pathways.
Later studies continued to examine B7-33 in cardiovascular models and in controlled-release biomaterials designed to reduce fibrotic encapsulation around implants.
RXFP1, ERK and Matrix Remodeling
One proposed mechanism involves RXFP1 signaling through receptor complexes and downstream activation of ERK1/2. This can influence matrix metalloproteinases, including MMP-2, which participate in extracellular-matrix turnover.
The biological model is therefore not simply “B7-33 reduces collagen.” Instead, the research examines how receptor signaling changes fibroblast behavior, collagen deposition and matrix-remodeling processes.
What Animal Studies Can and Cannot Show
Rodent fibrosis models are useful because they allow researchers to test tissue remodeling under controlled experimental conditions. They can reveal whether a pathway is biologically active and whether a candidate peptide changes measurable fibrosis endpoints.
However, animal models do not establish clinical efficacy in humans. Differences in disease biology, receptor distribution, pharmacokinetics and treatment timing can all affect whether a preclinical result translates.
B7-33 Compared with Native Relaxin
The main scientific attraction of B7-33 is structural simplification. Native relaxin-2 is a two-chain disulfide-bonded peptide, while B7-33 is a smaller single-chain analogue.
That simpler scaffold may make synthesis and research handling more straightforward, but the molecules should not be treated as interchangeable. B7-33 has a different signaling profile and does not reproduce every property of native relaxin.
Ongoing Optimization of the Relaxin Scaffold
Subsequent medicinal-chemistry work has continued to explore smaller relaxin-derived structures and modifications intended to improve potency, helicity, stability and receptor activity.
This broader research supports the idea that B7-33 is part of an evolving scaffold-development program rather than a final answer to RXFP1 pharmacology.
Analytical Considerations
B7-33 is a defined synthetic peptide, so research quality depends on confirming that the material matches the intended sequence and has an appropriate purity profile.
HPLC can help characterize chromatographic purity and related species, while mass spectrometry can support molecular identity. These methods answer different questions and are most useful when interpreted together.
See How Peptide Purity Is Tested and our peptide COA guide for more detail.
Research Limitations
The B7-33 evidence base has several important limitations:
- most published findings are preclinical rather than human clinical trials;
- different fibrosis models do not perfectly reproduce chronic human disease;
- RXFP1 signaling is cell-type dependent and can vary with receptor expression;
- results with B7-33 should not automatically be generalized to native relaxin or other relaxin analogues.
Key Research Takeaway
B7-33 is best understood as a compact relaxin-derived research peptide developed to probe RXFP1 signaling with a simpler, functionally selective molecular scaffold. Its most prominent research area is fibrosis, where multiple preclinical studies have reported effects on tissue remodeling and collagen-associated endpoints.
The mechanistic rationale is well developed, but the evidence remains primarily preclinical. That makes B7-33 valuable for studying RXFP1 biology and biased signaling while leaving major questions about human translation unresolved.
Research Product Information
Peps In Bulk lists B7-33 in 10-vial research packs. Current strength, pack and available batch-documentation information is shown on the product page.
References
- Hossain MA, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Br J Pharmacol. 2018.
- Alam F, et al. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother. 2023.
- Wang C, et al. Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation. 2019.
- Patil NA, et al. Further Developments towards a Minimal Potent Derivative of Human Relaxin-2. 2023.
For research and educational purposes only. This article is not medical advice.
